Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(16 sites)

United States

Apex Clinical Research Center, Mayfield Heights, Ohio

China

The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui

Peking University People's Hospital, Beijing, Beijing Municipality

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality

The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian

Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong

The First Hospital of Hebei Medical University, Shijiazhuang, Hebei

Jingzhou Central Hospital, Jingzhou, Hubei

Xiangya Hospital of Central South University, Changsha, Hunan

The first hospital of Jilin University, Changchun, Jilin

Shenyang Seventh People's Hospital, Shenyang, Liaoning

Shandong Provincial Dermatology Hospital, Jinan, Shandong

Chengdu Second People's Hospital, Chengdu, Sichuan

Sichuan Provincial People's Hospital, Chengdu, Sichuan

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, Tianjin Municipality

Affiliated Hangzhou First People's Hospital,School of Medicine ,Westlake University, Hangzhou, Zhejiang